Akili, Inc.

2024 Q1 Form 10-Q Financial Statement

#000095017024059580 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q1

Balance Sheet

Concept 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.16M
YoY Change -46.22%
Cash & Equivalents $63.16M
Short-Term Investments
Other Short-Term Assets $1.693M
YoY Change -55.87%
Inventory
Prepaid Expenses
Receivables $144.0K
Other Receivables $0.00
Total Short-Term Assets $65.00M
YoY Change -46.43%
LONG-TERM ASSETS
Property, Plant & Equipment $835.0K
YoY Change -1.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $90.00K
YoY Change 8900.0%
Total Long-Term Assets $2.367M
YoY Change -27.66%
TOTAL ASSETS
Total Short-Term Assets $65.00M
Total Long-Term Assets $2.367M
Total Assets $67.37M
YoY Change -45.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.101M
YoY Change -22.08%
Accrued Expenses $1.794M
YoY Change -36.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $7.500M
YoY Change 20.0%
Total Short-Term Liabilities $11.21M
YoY Change -1.82%
LONG-TERM LIABILITIES
Long-Term Debt $3.786M
YoY Change -64.26%
Other Long-Term Liabilities $23.00K
YoY Change -99.77%
Total Long-Term Liabilities $23.00K
YoY Change -99.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.21M
Total Long-Term Liabilities $23.00K
Total Liabilities $17.16M
YoY Change -46.65%
SHAREHOLDERS EQUITY
Retained Earnings -$309.5M
YoY Change 18.6%
Common Stock $8.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.21M
YoY Change
Total Liabilities & Shareholders Equity $67.37M
YoY Change -45.93%

Cashflow Statement

Concept 2024 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001850266
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40558
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Akili, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
92-3654772
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
71 Commercial Street
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Mailbox 312
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
CY2024Q1 dei City Area Code
CityAreaCode
617
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
313-8853
CY2024Q1 dei Security12b Title
Security12bTitle
Common stock, $0.0001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
AKLI
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63161000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75150000
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
180000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
305000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
144000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
300000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1513000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2275000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
64998000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
78030000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
835000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
680000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1442000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1577000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
383000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
113000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
90000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
96000
CY2024Q1 us-gaap Assets
Assets
67365000
CY2023Q4 us-gaap Assets
Assets
80383000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1101000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1285000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1794000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3326000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
38000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
779000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
756000
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
7500000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7500000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11212000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12967000
CY2024Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
1671000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3445000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1528000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1730000
CY2024Q1 akli Corporate Bond Net Of Bond Discount
CorporateBondNetOfBondDiscount
2115000
CY2023Q4 akli Corporate Bond Net Of Bond Discount
CorporateBondNetOfBondDiscount
2054000
CY2024Q1 akli Earn Out Liabilities Non Current
EarnOutLiabilitiesNonCurrent
608000
CY2023Q4 akli Earn Out Liabilities Non Current
EarnOutLiabilitiesNonCurrent
1632000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23000
CY2024Q1 us-gaap Liabilities
Liabilities
17157000
CY2023Q4 us-gaap Liabilities
Liabilities
21851000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78684864
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78684864
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78356527
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78356527
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
359744000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
358305000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309544000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-299781000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
50208000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
58532000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67365000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80383000
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
173000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
137000
CY2024Q1 us-gaap Gross Profit
GrossProfit
210000
CY2023Q1 us-gaap Gross Profit
GrossProfit
-24000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4183000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6084000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6892000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13011000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
11075000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
19095000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10865000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19119000
CY2024Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
667000
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1043000
CY2024Q1 us-gaap Interest Expense
InterestExpense
453000
CY2023Q1 us-gaap Interest Expense
InterestExpense
622000
CY2024Q1 akli Change In Estimated Fair Value Of Earn Out Liabilities
ChangeInEstimatedFairValueOfEarnOutLiabilities
888000
CY2023Q1 akli Change In Estimated Fair Value Of Earn Out Liabilities
ChangeInEstimatedFairValueOfEarnOutLiabilities
-2013000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1102000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1592000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9763000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20711000
CY2024Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-9763000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-20711000
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
23000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9763000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20688000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-9763000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-20711000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78526669
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78526669
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78079013
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78079013
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
58532000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1438000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-9763000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
50208000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
110679000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2449000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
23000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-20711000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
92440000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-9763000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-20711000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
75000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77000
CY2024Q1 akli Reduction In The Carrying Amount Of Right Of Use Assets
ReductionInTheCarryingAmountOfRightOfUseAssets
135000
CY2023Q1 akli Reduction In The Carrying Amount Of Right Of Use Assets
ReductionInTheCarryingAmountOfRightOfUseAssets
169000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1302000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2759000
CY2023Q1 akli Amortization Of Premium On Short Term Investments
AmortizationOfPremiumOnShortTermInvestments
-432000
CY2024Q1 akli Non Cash Interest Expense
NonCashInterestExpense
162000
CY2023Q1 akli Non Cash Interest Expense
NonCashInterestExpense
194000
CY2024Q1 akli Change In Fair Value Of Earn Out Liabilities
ChangeInFairValueOfEarnOutLiabilities
-888000
CY2023Q1 akli Change In Fair Value Of Earn Out Liabilities
ChangeInFairValueOfEarnOutLiabilities
2013000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-156000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-776000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1079000
CY2024Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-6000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-184000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1268000
CY2024Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1532000
CY2023Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2788000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-179000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-195000
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-62000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
14000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9996000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19098000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
CY2024Q1 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
227000
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
22082000
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
75000000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-230000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
52915000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2024Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
14000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
45000
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1875000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1888000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-45000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-12114000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
33772000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
75455000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54402000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63341000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88174000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
310000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
422000
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 akli Percentage Of Workforce Reduction Of Employees
PercentageOfWorkforceReductionOfEmployees
0.46
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309544000
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
63161000
CY2024Q1 akli Subscriptions Term
SubscriptionsTerm
P30D
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
383000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
113000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
100000
CY2024Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
129000
CY2024Q1 akli Contract With Customer Liability Revenue Deferred
ContractWithCustomerLiabilityRevenueDeferred
-191000
CY2024Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
38000
CY2024Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
454000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2355000
CY2024Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
139000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
150000
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
136000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
200000
CY2024Q1 akli Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
19000
CY2023Q4 akli Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
12000
CY2024Q1 akli Accrued Consulting Service Expenses
AccruedConsultingServiceExpenses
45000
CY2023Q4 akli Accrued Consulting Service Expenses
AccruedConsultingServiceExpenses
129000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1001000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
480000
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1794000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3326000
CY2024Q1 akli Subordinated Debt Gross
SubordinatedDebtGross
5000000
CY2023Q4 akli Subordinated Debt Gross
SubordinatedDebtGross
5000000
CY2024Q1 akli Unamortized Discount On Subordinated Debt
UnamortizedDiscountOnSubordinatedDebt
2885000
CY2023Q4 akli Unamortized Discount On Subordinated Debt
UnamortizedDiscountOnSubordinatedDebt
2946000
CY2024Q1 us-gaap Subordinated Long Term Debt
SubordinatedLongTermDebt
2115000
CY2023Q4 us-gaap Subordinated Long Term Debt
SubordinatedLongTermDebt
2054000
CY2024Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.123
CY2023Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.118
CY2024Q1 us-gaap Notes Payable Current
NotesPayableCurrent
7500000
CY2024Q1 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
750000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1302000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2759000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14591753
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.94
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M21D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
66000
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.25
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
513456
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.09
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
207238
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.01
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13937059
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M9D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7738868
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.81
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M25D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13937059
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y1M9D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3000
CY2024Q1 akli Fair Value Of Common Stock
FairValueOfCommonStock
0.25
CY2023Q1 akli Fair Value Of Common Stock
FairValueOfCommonStock
1.56
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0289
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9924
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M29D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M17D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0423
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0387
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.21
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.26
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
54000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
26000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023Q4 akli Business Combination Earn Out Liabilities Fair Value
BusinessCombinationEarnOutLiabilitiesFairValue
1632
CY2024Q1 akli Business Combination Increase Decrease In Fair Value Of Earn Out Liabilities
BusinessCombinationIncreaseDecreaseInFairValueOfEarnOutLiabilities
-1024
CY2024Q1 akli Business Combination Earn Out Liabilities Fair Value
BusinessCombinationEarnOutLiabilitiesFairValue
608
CY2024Q1 us-gaap Share Price
SharePrice
0.29
CY2024Q1 akli Expected Term Of Earn Out Share
ExpectedTermOfEarnOutShare
P3Y4M24D
CY2024Q1 akli Expected Volatility Rate Of Earn Out Shares
ExpectedVolatilityRateOfEarnOutShares
1.225
CY2024Q1 akli Expected Dividend Yield Of Earn Out Shares
ExpectedDividendYieldOfEarnOutShares
0
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9763
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9763
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20711
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20711
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78526669
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78526669
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78079013
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78079013
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26121972
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26644244
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 akli Rule10 B51 Arrangement Modified
Rule10B51ArrangementModified
false
CY2024Q1 akli Non Rule10 B51 Arrangement Modified
NonRule10B51ArrangementModified
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-059580-index-headers.html Edgar Link pending
0000950170-24-059580-index.html Edgar Link pending
0000950170-24-059580.txt Edgar Link pending
0000950170-24-059580-xbrl.zip Edgar Link pending
akli-20240331.htm Edgar Link pending
akli-20240331.xsd Edgar Link pending
akli-ex31_1.htm Edgar Link pending
akli-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
akli-20240331_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending